Prime Medicine Business Summary

Prime Medicine, Inc. (PRME) is a clinical-stage biotechnology company that generates revenue primarily through strategic research collaborations and licensing agreements, most notably with Bristol Myers Squibb and the Cystic Fibrosis Foundation. The company’s business model is centered on its proprietary Prime Editing platform, a "search-and-replace" gene editing technology designed to provide one-time curative therapies. Its primary business segments are organized by therapeutic application, including an in vivo liver franchise targeting Wilson’s Disease and Alpha-1 Antitrypsin Deficiency (AATD), a lung program for Cystic Fibrosis, and ex vivo partnered programs in hematology and oncology. Prime Medicine competes directly with gene editing pioneers such as Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Editas Medicine. It distinguishes itself in the market by offering a more precise and versatile editing capability than traditional CRISPR-Cas9, as it can perform all types of genetic substitutions, insertions, and deletions without requiring double-strand DNA breaks. The company was co-founded by David R. Liu, Ph.D., a renowned investigator at the Broad Institute of MIT and Harvard, and Andrew Anzalone, M.D., Ph.D., the lead developer of Prime Editing technology. The current leadership team is headed by CEO Allan Reine, M.D., who transitioned from the CFO role in May 2025, and Executive Chair Jeff Marrazzo, the co-founder and former CEO of Spark Therapeutics. Other key executives include Chief Technical Officer Ann Lee, Ph.D., formerly of Celgene and Juno Therapeutics, and Chief Business Officer Matthew Hawryluk, Ph.D. Prime Medicine is backed by a high-pedigree investor base including Arch Venture Partners, GV (Google Ventures), and F-Prime Capital. Its Board of Directors features prominent industry figures such as Robert Nelsen of Arch Venture Partners and David Schenkein, M.D., of GV, reflecting strong institutional support for its next-generation genomic medicine platform.